This article is more than 5 years old. Information may no longer be current.

Opko acquires rights to novel agent for treating ocular viral infections

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MIAMI — Opko Health has acquired exclusive worldwide rights to ophthalmic uses of a novel small molecule agent for treating viral conjunctivitis and other viral infections, the company announced in a press release.

The agent, called CTC-96 and also known as Doxovir, has demonstrated potent anti-viral activity and nonsteroidal anti-inflammatory properties with good safety in preclinical and phase 1 trials for treating adenovirus keratoconjunctivitis and ocular herpes infection, according to the release.

Developed by Redox Pharmaceutical, CTC-96 is currently in phase 2 clinical development for treating viral conjunctivitis and other viral infections.